{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Anavex Life Sciences Corp.
Is Anavex Life Sciences Corp. technically bullish or bearish?
As of January 29, 2025, the trend is mildly bullish, supported by daily moving averages and bullish Bollinger Bands, but tempered by a mildly bearish weekly MACD and bearish KST, indicating a cautious outlook.
Who are in the management team of Anavex Life Sciences Corp.?
As of March 2022, Anavex Life Sciences Corp. is led by Dr. Christopher Missling as CEO, with a Board of Directors that includes five independent members: Dr. Peter Donhauser, Mr. Elliot Favus, Mr. Athanasios Skarpelos, Dr. Steffen Thomas, and Dr. Claus van der Velden.
What does Anavex Life Sciences Corp. do?
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing therapeutics for neurodegenerative and neurodevelopmental diseases. It has a market cap of $761.52 million and reported a net loss of $11 million in its most recent quarter.
How big is Anavex Life Sciences Corp.?
As of Jun 18, Anavex Life Sciences Corp. has a market capitalization of 761.52 million and reported net sales of 0.00 million with a net profit of -47.14 million. Shareholder's Funds are 120.26 million and Total Assets are 135.57 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
